An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis

Trial Profile

An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2015

At a glance

  • Drugs Fedratinib (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Apr 2014 Planned End Date changed from 1 Mar 2014 to 1 Apr 2014, according to ClinicalTrials.gov record.
    • 09 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Mar 2014 according to ClinicalTrials.gov record.
    • 10 Dec 2013 Results reporting bone marrow fibrosis outcomes presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top